BioCryst Pharmaceuticals

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, Food and Drug Administration, Safety, Skin, Pharmacokinetics, Food, Commercial, Ataxia, FXN, Research, BioCryst Pharmaceuticals, Spark Therapeutics, ViroPharma, Pharmacist, Hereditary angioedema, OLE, Spark, Senior, Patient, FA, Gene expression, Database, BLA, Interim, Clinical trial, Therapy, Pharmacology, Pharmaceutical industry

In February 2024, Larimar raised net proceeds of approximately $161.8 million through a public offering of common stock.

Key Points: 
  • In February 2024, Larimar raised net proceeds of approximately $161.8 million through a public offering of common stock.
  • In March 2024, Larimar began to build its commercial team with the appointment of Frank Nazzario, RPh, as Vice President of Commercial.
  • Research and development expenses for the first quarter of 2024 were $12.9 million, compared to $4.6 million for the first quarter of 2023.
  • General and administrative expenses were $3.8 million in the first quarter of 2024, compared to $3.1 million in the first quarter of 2023.

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

Retrieved on: 
Donnerstag, Mai 9, 2024
University, International Society, Poster, BioCryst Pharmaceuticals, LTP, MD, History, Documentation, Hereditary angioedema, Patient, Medicine, HRU, HAE, Pharmacoeconomics, Disease, Pharmaceutical industry

“The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.

Key Points: 
  • “The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.
  • This outcome provides a compelling argument that ORLADEYO, which is known to be effective in reducing HAE morbidity, is also a cost-effective strategy for patient management.
  • The poster detailed findings from a retrospective real-world study that featured analysis of administrative claims data of patients with HAE in the United States.
  • We look forward to reporting additional real-world evidence that highlights the benefits associated with long-term prophylaxis with ORLADEYO,” said Dr. William Sheridan, chief development officer and interim chief medical officer of BioCryst.

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Dienstag, Mai 7, 2024
BioCryst Pharmaceuticals, Bank, Conference

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:
    Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m.
  • 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m.
  • Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m.
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday, May 20, 2024, at 10:30 a.m.

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Montag, Mai 6, 2024
Net, Skin, Investment, Solubility, Research, Diabetes, BioCryst Pharmaceuticals, Plasma, Injection, Webcast, Kallikrein, Prescription, Disease, Dehydration, Patient, Eye, Operating cost, Physician, Paratriathlon, EPS, Workforce, Infection, DME, Clinical trial, HAE, Diabetic retinopathy, Edema, Genetic disorder, GAAP, Netherton syndrome, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • These two successes helped us exceed our revenue projections for the quarter and, as a result, we are increasing our revenue guidance for 2024,” said Charlie Gayer, chief commercial officer of BioCryst.
  • Interest expense was $24.5 million in the first quarter of 2024, compared to $27.4 million in the first quarter of 2023 (-10.6 percent y-o-y).
  • Our references to our first quarter 2024 “non-GAAP pro forma” financial measures of adjusted net loss and adjusted earnings per share constitute non-GAAP financial measures.
  • ET today to discuss the financial results and provide a corporate update.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Freitag, Mai 3, 2024
BioCryst Pharmaceuticals, Employment

The options and RSUs were granted as of April 30, 2024, as inducements material to each employee entering into employment with BioCryst.

Key Points: 
  • The options and RSUs were granted as of April 30, 2024, as inducements material to each employee entering into employment with BioCryst.
  • The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $4.13 per share, which is equal to the closing price of BioCryst common stock on the grant date.
  • The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

BioCryst to Report First Quarter 2024 Financial Results on May 6

Retrieved on: 
Montag, April 22, 2024
BioCryst Pharmaceuticals, Webcast

RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.
  • BioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.
  • A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com .

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

Retrieved on: 
Mittwoch, April 17, 2024
BioCryst Pharmaceuticals, LATAM, Hereditary angioedema, Pint, Patient, ANVISA, Marketing, HAE, Brazilian Health Regulatory Agency, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.
  • “We are excited to announce that ORLADEYO is now approved in the region’s largest market, following the positive regulatory decisions we received in Chile and Argentina last year.
  • We look forward to working with our partner, Pint Pharma, to make ORLADEYO available in Brazil and across LATAM,” said Charlie Gayer, chief commercial officer of BioCryst.
  • BioCryst has an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO in the pan-Latin America region.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Mittwoch, April 3, 2024
Employment, BioCryst Pharmaceuticals

The options and RSUs were granted as of March 29, 2024, as inducements material to each employee entering into employment with BioCryst.

Key Points: 
  • The options and RSUs were granted as of March 29, 2024, as inducements material to each employee entering into employment with BioCryst.
  • The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $5.08 per share, which is equal to the closing price of BioCryst common stock on March 28, 2024, the last trading date prior to the grant date.
  • The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Montag, März 25, 2024
BioCryst Pharmaceuticals, Conference

RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m.
  • ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m.
  • ET.

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Dienstag, März 12, 2024
Patient, G&A, BioCryst Pharmaceuticals, Eye, Drug delivery, Clinical trial, AAO, Extension, Webcast, Pharming, CPT, Safety, Disease, SPA, American Academy of Ophthalmology, Compass, Insurance, Diabetic retinopathy, Conference call, Aura, AMD, TKI, CLS, FDA, Administration, Conference, SCS, DME, American Academy, OASIS, Injection, Research and development, Axitinib, Pharmaceutical industry

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
  • Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.